A Phase 3 interventional study of ibrutinib and Placebo in Chronic Graft Versus Host Disease, sponsored by Pharmacyclics LLC.. Completed at 102 sites in 15 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-03-30.
Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing ibrutinib in Bronchiolitis Obliterans Syndrome — none open to participants now, 1 under way, 1 of them phase 3. ibrutinib · Bronchiolitis Obliterans Syndrome.
Among the 11 studies testing ibrutinib in Bronchiolitis Obliterans Syndrome, this one is the 3rd largest by enrollment, is the only one that started in 2017, is one of 3 in phase 3, and was the 5th registered.
714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.
Browse Bronchiolitis Obliterans Syndrome studies →None of the 11 studies testing ibrutinib in Bronchiolitis Obliterans Syndrome is open now. The open studies under Bronchiolitis Obliterans Syndrome, anywhere →
ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 3
First in 2012; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 193 is above the median of 50 across 565 interventional studies indexed under Bronchiolitis Obliterans Syndrome.
Median enrollment 19 across the 11 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 11 have an industry lead sponsor. The 8 most frequent:
This study is registered under Pharmacyclics LLC., one of the names counted as AbbVie. Under that name alone:
Pharmacyclics LLC. is the lead sponsor of 54 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 9 (90%) have results posted.
AbbVie has 9 studies filed under Bronchiolitis Obliterans Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies testing ibrutinib in Bronchiolitis Obliterans Syndrome that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing ibrutinib in Bronchiolitis Obliterans Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the safety and efficacy of ibrutinib in combination with prednisone in subjects with newly diagnosed moderate to severe cGVHD.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ibrutinib (420 mg) given orally once daily continuously starting on Week 1 Day 1 until cGVHD progression, progression of underlying malignancy, participant begins another systemic treatment for cGVHD or unacceptable toxicity. The 420 mg dose was adjusted for cytochrome P450 \[CYP\] inhibitors or hepatic dysfunction as applicable. Prednisone 1 mg/kg/d given orally once daily continuously starting on Week 1 Day 1 until unacceptable toxicity or until participant is successfully tapered from the prednisone. Starting prednisone dose may be as low as 0.5 mg/kg/d if a participant cannot tolerate higher doses.
Drug: ibrutinib · Drug: Prednisone
Placebo given orally once daily continuously starting on Week 1 Day 1 until cGVHD progression, progression of underlying malignancy, participant begins another systemic treatment for cGVHD or unacceptable toxicity. Prednisone 1 mg/kg/d given orally once daily continuously starting on Week 1 Day 1 until unacceptable toxicity or until participant is successfully tapered from the prednisone. Starting prednisone dose may be as low as 0.5 mg/kg/d if a participant cannot tolerate higher doses.
Drug: Placebo · Drug: Prednisone
Ibrutinib capsules administered orally daily
Also known as: IMBRUVICA®, PCI-32765
Placebo capsules administered orally daily
Prednisone administered daily
Primary Analysis: Response Rate at 48 Weeks
Response rate was defined as the percentage of participants who were responders. Responders were defined as participants who had a complete response (CR) or a partial response (PR) at 48 weeks without starting any subsequent therapy for cGVHD or having evidence of relapse of their underlying disease that was indication for transplant prior to response assessment at 48 weeks. Response was defined using the National Institutes of Health (NIH) Consensus Panel Chronic GVHD Activity Assessment (2014). Skin, mouth, liver, upper and lower gastrointestinal, esophagus, lung, eye, and joint/fascia are the organs or sites considered in evaluating overall response. CR is defined as resolution of all manifestations in each organ or site. PR is defined as improvement in at least 1 organ or site without progression in any other organ or site.
Time frame: 48 weeks (Cumulatively up to 30 March 2020)
Final Analysis: Response Rate at 48 Weeks
Response rate was defined as the percentage of participants who were responders. Responders were defined as participants who had a complete response (CR) or a partial response (PR) at 48 weeks without starting any subsequent therapy for cGVHD or having evidence of relapse of their underlying disease that was indication for transplant prior to response assessment at 48 weeks. Response was defined using the National Institutes of Health (NIH) Consensus Panel Chronic GVHD Activity Assessment (2014). Skin, mouth, liver, upper and lower gastrointestinal, esophagus, lung, eye, and joint/fascia are the organs or sites considered in evaluating overall response. CR is defined as resolution of all manifestations in each organ or site. PR is defined as improvement in at least 1 organ or site without progression in any other organ or site.
Time frame: 48 weeks (Cumulatively up to 12 July 2021)
Primary Analysis: Cumulative Incidence of Withdrawal of All Corticosteroids for Treatment of cGVHD
The cumulative incidence of withdrawal of all corticosteroids (95% confidence interval \[CI\]) was calculated using SAS lifetest procedure adjusting for competing risks including death, cGVHD progression, relapse of underlying disease, and start of subsequent cGVHD therapy. Data presented are the estimated proportion of participants withdrawing all corticosteroids at given time point. The time to withdrawal of corticosteroids is computed from randomization date to the first date of withdrawal of all corticosteroids for treatment of cGVHD to 0 mg daily for at least 30 days.
Time frame: Months 3, 6, 9, 12, 15, 18, 21, 24 (Cumulatively up to 30 March 2020)
Final Analysis: Cumulative Incidence of Withdrawal of All Corticosteroids for Treatment of cGVHD
The cumulative incidence of withdrawal of all corticosteroids (95% confidence interval \[CI\]) was calculated using SAS lifetest procedure adjusting for competing risks including death, cGVHD progression, relapse of underlying disease, and start of subsequent cGVHD therapy. Data presented are the estimated proportion of participants withdrawing all corticosteroids at given time point. The time to withdrawal of corticosteroids is computed from randomization date to the first date of withdrawal of all corticosteroids for treatment of cGVHD to 0 mg daily for at least 30 days.
Time frame: Months 3, 6, 9, 12, 15, 18, 21, 24 (Cumulatively up to 12 July 2021)
Primary Analysis: Cumulative Incidence of Withdrawal of All Immunosuppressants
The cumulative incidence of withdrawal of all immunosuppressants (95% CI) was calculated using SAS lifetest procedure adjusting for competing risks including death, cGVHD progression, relapse of underlying disease, and start of subsequent cGVHD therapy. Data presented are the estimated proportion of participants withdrawing all immunosuppressants at a given time point. The time to withdrawal of all immunosuppressants is computed from randomization date to the first date of withdrawal of all immunosuppressants for treatment of cGVHD, sustained for at least 30 days. All immunosuppressants include corticosteroids but they do not include ibrutinib.
Time frame: Months 3, 6, 9, 12, 15, 18, 21, 24 (cumulatively up to 30 March 2020)
Final Analysis: Cumulative Incidence of Withdrawal of All Immunosuppressants
The cumulative incidence of withdrawal of all immunosuppressants (95% CI) was calculated using SAS lifetest procedure adjusting for competing risks including death, cGVHD progression, relapse of underlying disease, and start of subsequent cGVHD therapy. Data presented are the estimated proportion of participants withdrawing all immunosuppressants at a given time point. The time to withdrawal of all immunosuppressants is computed from randomization date to the first date of withdrawal of all immunosuppressants for treatment of cGVHD, sustained for at least 30 days. All immunosuppressants include corticosteroids but they do not include ibrutinib.
Time frame: Months 3, 6, 9, 12, 15, 18, 21, 24 (Cumulatively up to 12 July 2021)
Primary Analysis: Response Rate at 24 Weeks
Response rate was defined as the percentage of participants who were responders. Responders were defined as participants who had a CR or PR at 24 weeks without starting any subsequent therapy for cGVHD or having evidence of relapse of their underlying disease that was indication for transplant prior to response assessment at 24 weeks. Response was defined using the National Institutes of Health (NIH) Consensus Panel Chronic GVHD Activity Assessment (2014). Skin, mouth, liver, upper and lower gastrointestinal, esophagus, lung, eye, and joint/fascia are the organs or sites considered in evaluating overall response. CR is defined as resolution of all manifestations in each organ or site. PR is defined as improvement in at least 1 organ or site without progression in any other organ or site.
Time frame: 24 weeks (Cumulatively up to 30 March 2020)
Final Analysis: Response Rate at 24 Weeks
Response rate was defined as the percentage of participants who were responders. Responders were defined as participants who had a CR or PR at 24 weeks without starting any subsequent therapy for cGVHD or having evidence of relapse of their underlying disease that was indication for transplant prior to response assessment at 24 weeks. Response was defined using the National Institutes of Health (NIH) Consensus Panel Chronic GVHD Activity Assessment (2014). Skin, mouth, liver, upper and lower gastrointestinal, esophagus, lung, eye, and joint/fascia are the organs or sites considered in evaluating overall response. CR is defined as resolution of all manifestations in each organ or site. PR is defined as improvement in at least 1 organ or site without progression in any other organ or site.
Time frame: 24 weeks (Cumulatively up to 12 July 2021)
Primary Analysis: Percentage of Participants With Improvement in Overall Score on Lee cGVHD Symptom Scale at Two Consecutive Visits
Clinically meaningful improvement on Lee cGVHD symptom scale was defined as at least a 7-point decrease in Lee Symptom Scale overall summary score on at least 2 consecutive visits, not preceded by progressive disease, relapse of underlying disease or start of subsequent cGVHD treatment. The Lee cGVHD Symptom Scale score has 7 subscales (Skin, Eyes and Mouth, Breathing, Eating and Digestion, Muscles and Joints, Energy, and Mental and Emotional) with ratings as follows: 0- Not at all, 1- Slightly, 2 Moderately, 3 Quite a bit, 4-Extremely, with lower values representing a better outcome. A score is calculated for each subscale by taking the mean of all items completed if more than 50% were answered and normalizing to a 0 to 100 scale. An overall score is calculated as the average of these 7 subscales if at least 4 subscales have valid scores.
Time frame: Assessed at Weeks 5, 13, 25, 37, 49, 30 days after the last dose of study drug, and then every 12 weeks of follow-up until progressed disease. (Cumulatively up to 30 March 2020)
Final Analysis: Percentage of Participants With Improvement in Overall Score on Lee cGVHD Symptom Scale at Two Consecutive Visits
Clinically meaningful improvement on Lee cGVHD symptom scale was defined as at least a 7-point decrease in Lee Symptom Scale overall summary score on at least 2 consecutive visits, not preceded by progressive disease, relapse of underlying disease or start of subsequent cGVHD treatment. The Lee cGVHD Symptom Scale score has 7 subscales (Skin, Eyes and Mouth, Breathing, Eating and Digestion, Muscles and Joints, Energy, and Mental and Emotional) with ratings as follows: 0- Not at all, 1- Slightly, 2 Moderately, 3 Quite a bit, 4-Extremely, with lower values representing a better outcome. A score is calculated for each subscale by taking the mean of all items completed if more than 50% were answered and normalizing to a 0 to 100 scale. An overall score is calculated as the average of these 7 subscales if at least 4 subscales have valid scores.
Time frame: Assessed at Weeks 5, 13, 25, 37, 49, 30 days after the last dose of study drug, and then every 12 weeks of follow-up until progressed disease. (Cumulatively up to 12 July 2021)
Primary Analysis: Percentage of Participants Who Achieved Reduction of Prednisone Dose Level to Less Than 0.15 mg/kg/Day at 24 Weeks Sustained for at Least 30 Days
Time frame: 24 weeks (Cumulatively up to 30 March 2020)
Final Analysis: Percentage of Participants Who Achieved Reduction of Prednisone Dose Level to Less Than 0.15 mg/kg/Day at 24 Weeks Sustained for at Least 30 Days
Time frame: 24 weeks (Cumulatively up to 12 July 2021)
Primary Analysis: Overall Survival (OS)
OS was defined as the time of randomization until the time of death due to any cause, in months.
Time frame: Median time on study (cumulatively up to 30 March 2020) was 19.8 months and 18.4 months for the Ibrutinib + Prednisone and Placebo + Prednisone arms, respectively.
Final Analysis: OS
OS was defined as the time of randomization until the time of death due to any cause, in months.
Time frame: Median time on study (cumulatively up to 12 July 2021) was 33.1 months and 32.5 months for the Ibrutinib + Prednisone and Placebo + Prednisone arms, respectively.
Primary Analysis: Duration of Response (DOR) for Participants Who Had PR or CR at Any Time
Response was defined using the NIH Consensus Panel Chronic GVHD Activity Assessment (2014). Skin, mouth, liver, upper and lower GI, esophagus, lung, eye, and joint/fascia are the organs or sites considered in evaluating overall response. CR was defined as resolution of all manifestations in each organ or site. PR was defined as improvement in at least 1 organ or site without progression in any other organ or site. Duration of response was estimated by Kaplan-Meier methodology.
Time frame: Response was assessed every 4 weeks from Week 5 through Week 25, Week 37, Week 49, 30 days after the last dose of study drug, and then every 12 weeks of follow-up until progressed disease. (Cumulatively up to 30 March 2020)
Final Analysis: DOR for Participants Who Had PR or CR at Any Time
Response was defined using the NIH Consensus Panel Chronic GVHD Activity Assessment (2014). Skin, mouth, liver, upper and lower GI, esophagus, lung, eye, and joint/fascia are the organs or sites considered in evaluating overall response. CR was defined as resolution of all manifestations in each organ or site. PR was defined as improvement in at least 1 organ or site without progression in any other organ or site. Duration of response was estimated by Kaplan-Meier methodology.
Time frame: Response was assessed every 4 weeks from Week 5 through Week 25, Week 37, Week 49, 30 days after the last dose of study drug, and then every 12 weeks of follow-up until progressed disease. (Cumulatively up to 12 July 2021)
Primary Analysis: Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious AEs (SAEs), and Discontinuations Due to AEs Placebo in Combination With Prednisone
AE: any untoward medical occurrence, which does not necessarily have a causal relationship with this treatment. SAE: any untoward medical occurrence that at any dose: results in death; is life-threatening; requires in-patient hospitalization \>24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. Severity was graded according to the Common Terminology Criteria for Adverse Events version 4.03 (grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening, grade 5=death). Treatment-related events are those that were possibly related or related to study treatment per investigator's judgment. Treatment emergent AEs (TEAEs) occurred from the first dose of study drug up to 30 days after the last dose of study drug.
Time frame: From first dose of study drug through the end of treatment plus 30 days. As of data cutoff (cumulatively up to 30 March 2020), median ibrutinib treatment duration was 5.4 months and the median placebo treatment duration was 6.4 months.
Final Analysis: Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious AEs (SAEs), and Discontinuations Due to AEs Placebo in Combination With Prednisone
AE: any untoward medical occurrence, which does not necessarily have a causal relationship with this treatment. SAE: any untoward medical occurrence that at any dose: results in death; is life-threatening; requires in-patient hospitalization \>24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. Severity was graded according to the Common Terminology Criteria for Adverse Events version 4.03 (grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening, grade 5=death). Treatment-related events are those that were possibly related or related to study treatment per investigator's judgment. Treatment emergent AEs (TEAEs) occurred from the first dose of study drug up to 30 days after the last dose of study drug.
Time frame: From first dose of study drug through the end of treatment plus 30 days. As of data cutoff (cumulatively up to 12 July 2021), median ibrutinib treatment duration was 5.4 months and the median placebo treatment duration was 6.4 months.
Participants were enrolled at 66 sites overall: 24 sites in North America, and 42 sites in the rest of the world.
| Milestone | Ibrutinib + Prednisone | Placebo + Prednisone |
|---|---|---|
| Started | 95 | 98 |
| Received at least 1 dose of study drug | 94 | 96 |
| Completed | 95 | 98 |
| Not completed | 0 | 0 |
Response rate was defined as the percentage of participants who were responders. Responders were defined as participants who had a complete response (CR) or a partial response (PR) at 48 weeks without starting any subsequent therapy for cGVHD or having evidence of relapse of their underlying disease that was indication for transplant prior to response assessment at 48 weeks. Response was defined using the National Institutes of Health (NIH) Consensus Panel Chronic GVHD Activity Assessment (2014). Skin, mouth, liver, upper and lower gastrointestinal, esophagus, lung, eye, and joint/fascia are the organs or sites considered in evaluating overall response. CR is defined as resolution of all manifestations in each organ or site. PR is defined as improvement in at least 1 organ or site without progression in any other organ or site.
| percentage of participants | Ibrutinib + Prednisone | Placebo + Prednisone |
|---|---|---|
| Primary Analysis: Response Rate at 48 Weeks | 41.1 | 36.7 |
Response rate was defined as the percentage of participants who were responders. Responders were defined as participants who had a complete response (CR) or a partial response (PR) at 48 weeks without starting any subsequent therapy for cGVHD or having evidence of relapse of their underlying disease that was indication for transplant prior to response assessment at 48 weeks. Response was defined using the National Institutes of Health (NIH) Consensus Panel Chronic GVHD Activity Assessment (2014). Skin, mouth, liver, upper and lower gastrointestinal, esophagus, lung, eye, and joint/fascia are the organs or sites considered in evaluating overall response. CR is defined as resolution of all manifestations in each organ or site. PR is defined as improvement in at least 1 organ or site without progression in any other organ or site.
| percentage of participants | Ibrutinib + Prednisone | Placebo + Prednisone |
|---|---|---|
| Final Analysis: Response Rate at 48 Weeks | 41.1 | 36.7 |
The cumulative incidence of withdrawal of all corticosteroids (95% confidence interval \[CI\]) was calculated using SAS lifetest procedure adjusting for competing risks including death, cGVHD progression, relapse of underlying disease, and start of subsequent cGVHD therapy. Data presented are the estimated proportion of participants withdrawing all corticosteroids at given time point. The time to withdrawal of corticosteroids is computed from randomization date to the first date of withdrawal of all corticosteroids for treatment of cGVHD to 0 mg daily for at least 30 days.
| proportion of participants | Ibrutinib + Prednisone | Placebo + Prednisone |
|---|---|---|
| 3 Months | 0.042 (0.014 to 0.097) | 0.021 (0.004 to 0.066) |
| 6 Months | 0.229 (0.149 to 0.320) | 0.216 (0.140 to 0.304) |
| 9 Months | 0.318 (0.225 to 0.415) | 0.322 (0.231 to 0.417) |
| 12 Months | 0.392 (0.290 to 0.492) | 0.356 (0.260 to 0.453) |
| 15 Months | 0.419 (0.314 to 0.520) | 0.356 (0.260 to 0.453) |
| 18 Months | 0.419 (0.314 to 0.520) | 0.356 (0.260 to 0.453) |
| 21 Months | — | 0.425 (0.299 to 0.545) |
| 24 Months | — | 0.425 (0.299 to 0.545) |
The cumulative incidence of withdrawal of all corticosteroids (95% confidence interval \[CI\]) was calculated using SAS lifetest procedure adjusting for competing risks including death, cGVHD progression, relapse of underlying disease, and start of subsequent cGVHD therapy. Data presented are the estimated proportion of participants withdrawing all corticosteroids at given time point. The time to withdrawal of corticosteroids is computed from randomization date to the first date of withdrawal of all corticosteroids for treatment of cGVHD to 0 mg daily for at least 30 days.
| proportion of participants | Ibrutinib + Prednisone | Placebo + Prednisone |
|---|---|---|
| 3 Months | 0.042 (0.014 to 0.097) | 0.021 (0.004 to 0.066) |
| 6 Months | 0.218 (0.140 to 0.308) | 0.219 (0.142 to 0.307) |
| 9 Months | 0.318 (0.225 to 0.414) | 0.326 (0.234 to 0.422) |
| 12 Months | 0.406 (0.305 to 0.505) | 0.359 (0.263 to 0.455) |
| 15 Months | 0.439 (0.336 to 0.538) | 0.359 (0.263 to 0.455) |
| 18 Months | 0.450 (0.346 to 0.549) | 0.369 (0.272 to 0.466) |
| 21 Months | 0.495 (0.388 to 0.593) | 0.391 (0.292 to 0.489) |
| 24 Months | 0.495 (0.388 to 0.593) | 0.391 (0.292 to 0.489) |
The cumulative incidence of withdrawal of all immunosuppressants (95% CI) was calculated using SAS lifetest procedure adjusting for competing risks including death, cGVHD progression, relapse of underlying disease, and start of subsequent cGVHD therapy. Data presented are the estimated proportion of participants withdrawing all immunosuppressants at a given time point. The time to withdrawal of all immunosuppressants is computed from randomization date to the first date of withdrawal of all immunosuppressants for treatment of cGVHD, sustained for at least 30 days. All immunosuppressants include corticosteroids but they do not include ibrutinib.
| proportion of participants | Ibrutinib + Prednisone | Placebo + Prednisone |
|---|---|---|
| 3 Months | 0.011 (0.001 to 0.052) | 0.000 (NA to NA) |
| 6 Months | 0.142 (0.079 to 0.222) | 0.134 (0.075 to 0.210) |
| 9 Months | 0.220 (0.141 to 0.310) | 0.207 (0.132 to 0.294) |
| 12 Months | 0.256 (0.170 to 0.350) | 0.241 (0.160 to 0.331) |
| 15 Months | 0.285 (0.193 to 0.383) | 0.241 (0.160 to 0.331) |
| 18 Months | 0.313 (0.210 to 0.422) | 0.241 (0.160 to 0.331) |
| 21 Months | 0.376 (0.252 to 0.499) | 0.268 (0.174 to 0.370) |
| 24 Months | 0.421 (0.280 to 0.556) | 0.268 (0.174 to 0.370) |
The cumulative incidence of withdrawal of all immunosuppressants (95% CI) was calculated using SAS lifetest procedure adjusting for competing risks including death, cGVHD progression, relapse of underlying disease, and start of subsequent cGVHD therapy. Data presented are the estimated proportion of participants withdrawing all immunosuppressants at a given time point. The time to withdrawal of all immunosuppressants is computed from randomization date to the first date of withdrawal of all immunosuppressants for treatment of cGVHD, sustained for at least 30 days. All immunosuppressants include corticosteroids but they do not include ibrutinib.
| proportion of participants | Ibrutinib + Prednisone | Placebo + Prednisone |
|---|---|---|
| 3 Months | 0.011 (0.001 to 0.052) | 0.000 (NA to NA) |
| 6 Months | 0.143 (0.080 to 0.224) | 0.136 (0.076 to 0.213) |
| 9 Months | 0.222 (0.142 to 0.313) | 0.221 (0.143 to 0.309) |
| 12 Months | 0.280 (0.191 to 0.375) | 0.264 (0.179 to 0.356) |
| 15 Months | 0.314 (0.220 to 0.412) | 0.274 (0.188 to 0.367) |
| 18 Months | 0.349 (0.251 to 0.448) | 0.285 (0.197 to 0.379) |
| 21 Months | 0.372 (0.272 to 0.472) | 0.307 (0.216 to 0.402) |
| 24 Months | 0.406 (0.303 to 0.507) | 0.307 (0.216 to 0.402) |
Response rate was defined as the percentage of participants who were responders. Responders were defined as participants who had a CR or PR at 24 weeks without starting any subsequent therapy for cGVHD or having evidence of relapse of their underlying disease that was indication for transplant prior to response assessment at 24 weeks. Response was defined using the National Institutes of Health (NIH) Consensus Panel Chronic GVHD Activity Assessment (2014). Skin, mouth, liver, upper and lower gastrointestinal, esophagus, lung, eye, and joint/fascia are the organs or sites considered in evaluating overall response. CR is defined as resolution of all manifestations in each organ or site. PR is defined as improvement in at least 1 organ or site without progression in any other organ or site.
| percentage of participants | Ibrutinib + Prednisone | Placebo + Prednisone |
|---|---|---|
| Primary Analysis: Response Rate at 24 Weeks | 47.4 | 54.1 |
Response rate was defined as the percentage of participants who were responders. Responders were defined as participants who had a CR or PR at 24 weeks without starting any subsequent therapy for cGVHD or having evidence of relapse of their underlying disease that was indication for transplant prior to response assessment at 24 weeks. Response was defined using the National Institutes of Health (NIH) Consensus Panel Chronic GVHD Activity Assessment (2014). Skin, mouth, liver, upper and lower gastrointestinal, esophagus, lung, eye, and joint/fascia are the organs or sites considered in evaluating overall response. CR is defined as resolution of all manifestations in each organ or site. PR is defined as improvement in at least 1 organ or site without progression in any other organ or site.
| percentage of participants | Ibrutinib + Prednisone | Placebo + Prednisone |
|---|---|---|
| Final Analysis: Response Rate at 24 Weeks | 47.4 | 54.1 |
Clinically meaningful improvement on Lee cGVHD symptom scale was defined as at least a 7-point decrease in Lee Symptom Scale overall summary score on at least 2 consecutive visits, not preceded by progressive disease, relapse of underlying disease or start of subsequent cGVHD treatment. The Lee cGVHD Symptom Scale score has 7 subscales (Skin, Eyes and Mouth, Breathing, Eating and Digestion, Muscles and Joints, Energy, and Mental and Emotional) with ratings as follows: 0- Not at all, 1- Slightly, 2 Moderately, 3 Quite a bit, 4-Extremely, with lower values representing a better outcome. A score is calculated for each subscale by taking the mean of all items completed if more than 50% were answered and normalizing to a 0 to 100 scale. An overall score is calculated as the average of these 7 subscales if at least 4 subscales have valid scores.
| percentage of participants | Ibrutinib + Prednisone | Placebo + Prednisone |
|---|---|---|
| Primary Analysis: Percentage of Participants With Improvement in Overall Score on Lee cGVHD Symptom Scale at Two Consecutive Visits | 38.9 | 26.5 |
Clinically meaningful improvement on Lee cGVHD symptom scale was defined as at least a 7-point decrease in Lee Symptom Scale overall summary score on at least 2 consecutive visits, not preceded by progressive disease, relapse of underlying disease or start of subsequent cGVHD treatment. The Lee cGVHD Symptom Scale score has 7 subscales (Skin, Eyes and Mouth, Breathing, Eating and Digestion, Muscles and Joints, Energy, and Mental and Emotional) with ratings as follows: 0- Not at all, 1- Slightly, 2 Moderately, 3 Quite a bit, 4-Extremely, with lower values representing a better outcome. A score is calculated for each subscale by taking the mean of all items completed if more than 50% were answered and normalizing to a 0 to 100 scale. An overall score is calculated as the average of these 7 subscales if at least 4 subscales have valid scores.
| percentage of participants | Ibrutinib + Prednisone | Placebo + Prednisone |
|---|---|---|
| Final Analysis: Percentage of Participants With Improvement in Overall Score on Lee cGVHD Symptom Scale at Two Consecutive Visits | 43.2 | 30.6 |
| percentage of participants | Ibrutinib + Prednisone | Placebo + Prednisone |
|---|---|---|
| Primary Analysis: Percentage of Participants Who Achieved Reduction of Prednisone Dose Level to Less Than 0.15 mg/kg/Day at 24 Weeks Sustained for at Least 30 Days | 40.0 | 45.9 |
| percentage of participants | Ibrutinib + Prednisone | Placebo + Prednisone |
|---|---|---|
| Final Analysis: Percentage of Participants Who Achieved Reduction of Prednisone Dose Level to Less Than 0.15 mg/kg/Day at 24 Weeks Sustained for at Least 30 Days | 41.1 | 45.9 |
OS was defined as the time of randomization until the time of death due to any cause, in months.
| months | Ibrutinib + Prednisone | Placebo + Prednisone |
|---|---|---|
| Primary Analysis: Overall Survival (OS) | NA (30.0 to NA) | NA (NA to NA) |
OS was defined as the time of randomization until the time of death due to any cause, in months.
| months | Ibrutinib + Prednisone | Placebo + Prednisone |
|---|---|---|
| Final Analysis: OS | NA (NA to NA) | NA (NA to NA) |
Response was defined using the NIH Consensus Panel Chronic GVHD Activity Assessment (2014). Skin, mouth, liver, upper and lower GI, esophagus, lung, eye, and joint/fascia are the organs or sites considered in evaluating overall response. CR was defined as resolution of all manifestations in each organ or site. PR was defined as improvement in at least 1 organ or site without progression in any other organ or site. Duration of response was estimated by Kaplan-Meier methodology.
| months | Ibrutinib + Prednisone | Placebo + Prednisone |
|---|---|---|
| Primary Analysis: Duration of Response (DOR) for Participants Who Had PR or CR at Any Time | 19.8 (7.4 to NA) | 10.0 (6.5 to 13.1) |
Response was defined using the NIH Consensus Panel Chronic GVHD Activity Assessment (2014). Skin, mouth, liver, upper and lower GI, esophagus, lung, eye, and joint/fascia are the organs or sites considered in evaluating overall response. CR was defined as resolution of all manifestations in each organ or site. PR was defined as improvement in at least 1 organ or site without progression in any other organ or site. Duration of response was estimated by Kaplan-Meier methodology.
| months | Ibrutinib + Prednisone | Placebo + Prednisone |
|---|---|---|
| Final Analysis: DOR for Participants Who Had PR or CR at Any Time | 19.1 (7.4 to NA) | 10.2 (6.5 to 17.1) |
AE: any untoward medical occurrence, which does not necessarily have a causal relationship with this treatment. SAE: any untoward medical occurrence that at any dose: results in death; is life-threatening; requires in-patient hospitalization \>24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. Severity was graded according to the Common Terminology Criteria for Adverse Events version 4.03 (grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening, grade 5=death). Treatment-related events are those that were possibly related or related to study treatment per investigator's judgment. Treatment emergent AEs (TEAEs) occurred from the first dose of study drug up to 30 days after the last dose of study drug.
| Participants | Ibrutinib + Prednisone | Placebo + Prednisone |
|---|---|---|
| Any TEAE | 93 | 95 |
| Any Grade ≥ 3 TEAE | 60 | 64 |
| Any Ibrutinib-/Placebo-Related TEAE | 66 | 58 |
| Any Grade ≥ 3 Ibrutinib-/Placebo-Related TEAE | 32 | 28 |
| Any Corticosteroid-Related TEAE | 71 | 77 |
| Any Grade ≥ 3 Corticosteroid-Related TEAE | 32 | 36 |
| Any TEAE Leading to Discontinuation (DC) of Any Treatment | 21 | 24 |
| Any TEAE Leading to DC of Ibrutinib/Placebo | 21 | 23 |
| Any TEAE Leading to DC of Corticosteroid | 8 | 8 |
| Any Treatment Emergent SAE (TESAE) | 46 | 48 |
| Any Grade ≥ 3 TESAE | 43 | 46 |
| Any Treatment-Related TESAE | 27 | 28 |
| Any Ibrutinib/Placebo Treatment-Related TESAE | 24 | 19 |
| Any Corticosteroid Treatment-Related TESAE | 24 | 27 |
| Any Fatal TEAE | 10 | 7 |
AE: any untoward medical occurrence, which does not necessarily have a causal relationship with this treatment. SAE: any untoward medical occurrence that at any dose: results in death; is life-threatening; requires in-patient hospitalization \>24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. Severity was graded according to the Common Terminology Criteria for Adverse Events version 4.03 (grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening, grade 5=death). Treatment-related events are those that were possibly related or related to study treatment per investigator's judgment. Treatment emergent AEs (TEAEs) occurred from the first dose of study drug up to 30 days after the last dose of study drug.
| Participants | Ibrutinib + Prednisone | Placebo + Prednisone |
|---|---|---|
| Any TEAE | 93 | 95 |
| Any Grade ≥ 3 TEAE | 64 | 64 |
| Any Ibrutinib-/Placebo-Related TEAE | 67 | 57 |
| Any Grade ≥ 3 Ibrutinib-/Placebo-Related TEAE | 35 | 27 |
| Any Corticosteroid-Related TEAE | 72 | 76 |
| Any Grade ≥ 3 Corticosteroid-Related TEAE | 34 | 35 |
| Any TEAE Leading to Discontinuation (DC) of Any Treatment | 23 | 28 |
| Any TEAE Leading to DC of Ibrutinib/Placebo | 22 | 27 |
| Any TEAE Leading to DC of Corticosteroid | 10 | 9 |
| Any Treatment Emergent SAE (TESAE) | 49 | 47 |
| Any Grade ≥ 3 TESAE | 46 | 45 |
| Any Treatment-Related TESAE | 29 | 27 |
| Any Ibrutinib/Placebo Treatment-Related TESAE | 26 | 18 |
| Any Corticosteroid Treatment-Related TESAE | 26 | 26 |
| Any Fatal TEAE | 12 | 6 |
Collected over From first dose of study drug through the end of treatment plus 30 days. As of data cutoff (cumulatively up to 12 July 2021), median ibrutinib treatment duration was 5.4 months and the median placebo treatment duration was 6.4 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ibrutinib | 23/94 (24.5%) | 51/94 (54.3%) | 88/94 (93.6%) |
| Placebo | 22/96 (22.9%) | 49/96 (51%) | 92/96 (95.8%) |
| Event | Ibrutinib | Placebo |
|---|---|---|
| PNEUMONIAInfections and infestations | 6/94 | 9/96 |
| INFLUENZAInfections and infestations | 4/94 | 4/96 |
| ACUTE MYELOID LEUKAEMIA RECURRENTNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/94 | 4/96 |
| PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders | 0/94 | 4/96 |
| CHRONIC GRAFT VERSUS HOST DISEASEImmune system disorders | 3/94 | 3/96 |
| CELLULITISInfections and infestations | 3/94 | 0/96 |
| PYREXIAGeneral disorders | 1/94 | 3/96 |
| GRAFT VERSUS HOST DISEASEImmune system disorders | 0/94 | 3/96 |
| PERICARDIAL EFFUSIONCardiac disorders | 2/94 | 0/96 |
| DIARRHOEAGastrointestinal disorders | 2/94 | 1/96 |
| Event | Ibrutinib | Placebo |
|---|---|---|
| COUGHRespiratory, thoracic and mediastinal disorders | 21/94 | 29/96 |
| INSOMNIAPsychiatric disorders | 26/94 | 18/96 |
| OEDEMA PERIPHERALGeneral disorders | 25/94 | 13/96 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 18/94 | 15/96 |
| FATIGUEGeneral disorders | 17/94 | 18/96 |
| MUSCLE SPASMSMusculoskeletal and connective tissue disorders | 17/94 | 16/96 |
| PYREXIAGeneral disorders | 7/94 | 16/96 |
| ALANINE AMINOTRANSFERASE INCREASEDInvestigations | 7/94 | 16/96 |
| VOMITINGGastrointestinal disorders | 15/94 | 8/96 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 15/94 | 15/96 |
| Age, Continuous(years) | Ibrutinib + Prednisone | Placebo + Prednisone | Total |
|---|---|---|---|
| Mean | 50.0 ± 14.48 | 51.1 ± 14.99 | 50.6 ± 14.71 |
| Sex: Female, Male(Participants) | Ibrutinib + Prednisone | Placebo + Prednisone | Total |
|---|---|---|---|
| Female | 34 | 33 | 67 |
| Male | 61 | 65 | 126 |
| Ethnicity (NIH/OMB)(Participants) | Ibrutinib + Prednisone | Placebo + Prednisone | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 2 | 7 |
| Not Hispanic or Latino | 78 | 78 | 156 |
| Unknown or Not Reported | 12 | 18 | 30 |
| Race (NIH/OMB)(Participants) | Ibrutinib + Prednisone | Placebo + Prednisone | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 27 | 19 | 46 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 6 | 4 | 10 |
| White | 47 | 58 | 105 |
| More than one race | 1 | 1 | 2 |
| Unknown or Not Reported | 12 | 16 | 28 |
Showing the first 100 of 102 sites across 15 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Requests for access to individual participant data from clinical studies conducted by Pharmacyclics LLC, an AbbVie Company, can be submitted through Yale Open Data Access (YODA) Project site at the following link.
Data sharing details ↗ · yoda.yale.edu
Ran from May 2017 to primary completion in Mar 2020, 34 months.
Results were first posted in May 2021, 1 year 1 month after primary completion.
Of 30 phase 3 interventional studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 62. This study's 34 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibrutinib
Bronchiolitis Obliterans Syndrome →